Loading clinical trials...
Loading clinical trials...
To assess safety and efficacy of the patients with MR4 therapy in GVHD prophylaxis study who are eligible for the administration after 100 days post transplant (up to 1 year)
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Astellas Pharma Inc
NCT03148743 · Acute-graft-versus-host Disease
NCT04431479 · Chronic Graft Versus Host Disease
NCT06996119 · Acute Myeloid Leukemia, Graft Versus Host Disease, and more
NCT06008808 · Graft Vs Host Disease, Graft-versus-host-disease, and more
NCT06705062 · Allogeneic Hematopoietic Cell Transplant, Graft Versus Host Disease
Chubu Region
Hokkaido Region
Kanto Region
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions